{"ticker": {"uuid": "7f25cfb9-fcb8-4056-93cd-e56ec2b3d3a2", "symbol": "MPLT", "name": "MapLight Therapeutics, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Form 144 MapLight Therapeutics For: 15 July By Investing.com", "summary": "This article reports on a Form 144 filing for MapLight Therapeutics on July 15. It is a very brief announcement, primarily consisting of the headline repeated in the body. The article originates from Investing.com and was published on July 15, 2026.", "url": "https://ng.investing.com/news/stock-market-news/form-144-maplight-therapeutics-for-15-july-93CH-2601605", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T21:14:00", "published_display": "15 Jul 2026 21:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maplight Therapeutics (NASDAQ:MPLT) Trading Down 5.4% - Here's What Happened", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPLTJOQjBVY1FhOFJHNFRmdUtXUU1TcnhmcVNLV1luVnUwQ210VnFxdTBTMjZXQ05SX05tZDdqc0JMX1NfU3NhazlTeVlWWXQ0ZjNBeTFvME5mbWp5anRibmxzcE9CRmZMRkRNZV9tUHJPU1p1bElnamtYNXBYWkllTW9fWkVaMzE3Mk96T0RKYmlOWHRkTW1tTW9tWlR4eER5dHA3NUhwN2c5N0dUX3prTm9fUVY0ekoxN2RrSXBLdw?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-15T16:26:57+00:00", "published_display": "15 Jul 2026 16:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Raises Target Price to $45", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNZEVNVkJ6T2k1Y21nR1J1Qlczakh1ZWxIVGJJRHQwbDE2NzZhOVVZNURrbEMxR2UzZ3AzbS1BUnJWcXh6enhtMGN2VnFLMmsxZVFmMjhSQ2V5TzZLejNBRGNIejk0dU1EV3VpX3hRMmgxNzhzZWRIcTZJaGpST19ua0VXNXZUb01Ga0k1RVlkZzRYaWxtTEVtQVVBR2lkSHJJc2Z2dWVWdnU5VzJORkRNdXdaUHJGSWJC?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-14T05:36:46+00:00", "published_display": "14 Jul 2026 05:36", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maplight Therapeutics (NASDAQ:MPLT) Sees Large Volume Increase on Analyst Upgrade", "summary": "Maplight Therapeutics (NASDAQ:MPLT) experienced a significant increase in trading volume after Needham & Company raised its price target and reaffirmed a buy rating. Despite positive analyst sentiment, with a consensus \"Buy\" rating and an average price target of $39.10, the compa", "url": "https://www.marketbeat.com/instant-alerts/maplight-therapeutics-nasdaqmplt-sees-large-volume-increase-on-analyst-upgrade-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T15:39:17", "published_display": "10 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham & Company LLC Raises Maplight Therapeutics (NASDAQ:MPLT) Price Target to $45.00", "summary": "Needham & Company LLC has increased its price target for Maplight Therapeutics (NASDAQ:MPLT) from $42.00 to $45.00, maintaining a \"buy\" rating and suggesting a 13.07% potential upside. This comes amidst a mixed analyst sentiment, with several firms reiterating \"buy\" ratings while", "url": "https://www.marketbeat.com/instant-alerts/needham-company-llc-raises-maplight-therapeutics-nasdaqmplt-price-target-to-4500-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T12:39:18", "published_display": "10 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham raises MapLight Therapeutics stock price target on trial data By Investing.com", "summary": "Needham has increased its price target for MapLight Therapeutics (NASDAQ:MPLT) to $45 from $42, maintaining a Buy rating. This adjustment comes as the firm raised the probability of success for MPLT's lead schizophrenia candidate, ML-007-MC, from 55% to 60%, with promising early ", "url": "https://ca.investing.com/news/stock-market-news/needham-raises-maplight-therapeutics-stock-price-target-on-trial-data-93CH-4729097", "source_name": "Investing.com Canada", "published_at": "2026-07-10T11:40:18", "published_display": "10 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MPLT - MapLight Therapeutics Inc Options", "summary": "This page provides a detailed financial overview of MapLight Therapeutics Inc (MPLT), including its last closing price, key financial metrics such as market cap, income, and sales, and various performance indicators. It also presents information on ownership, profitability, and s", "url": "https://finviz.com/stock?t=MPLT&ty=oc", "source_name": "Finviz", "published_at": "2026-07-05T05:41:23", "published_display": "05 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T15:08:06+00:00", "published_display": "04 Jul 2026 15:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of MapLight Therapeutics, Inc. \u2013 NASDAQ:MPLT", "summary": "This article focuses on the enterprise value to EBIT forward for MapLight Therapeutics, Inc. (NASDAQ: MPLT). It appears to be a financial data page from TradingView, providing financial oversight for the company. The content primarily lists navigation links and disclaimers rather", "url": "https://www.tradingview.com/symbols/NASDAQ-MPLT/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T08:11:24", "published_display": "01 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?", "summary": "MapLight Therapeutics, Inc. (MPLT) is considered a top biotech stock by analysts, with Raymond James initiating a \"Strong Buy\" rating and a $46 price target. The company has upcoming catalysts including the Phase 2 ZEPHYR trial readout for ML-007C-MA by mid-August and an Alzheime", "url": "https://uk.finance.yahoo.com/news/maplight-therapeutics-inc-mplt-stock-132231577.html", "source_name": "Market source", "published_at": "2026-06-30T15:38:59", "published_display": "30 Jun 2026 15:38", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of MapLight Therapeutics, Inc. \u2013 NASDAQ:MPLT", "summary": "This article provides details on how to find the number of shareholders for MapLight Therapeutics, Inc. (NASDAQ: MPLT) on TradingView. It directs users to the financial section of the company's profile where this information would typically be located, alongside other financial d", "url": "https://www.tradingview.com/symbols/NASDAQ-MPLT/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-30T04:09:31", "published_display": "30 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of MapLight Therapeutics, Inc. \u2013 NASDAQ:MPLT", "summary": "This article provides financial information for MapLight Therapeutics, Inc. (NASDAQ: MPLT), specifically focusing on its forward price-to-book ratio. The content states that the market for MPLT is currently closed with no trades. It appears to be a stub or data-oriented page from", "url": "https://www.tradingview.com/symbols/NASDAQ-MPLT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:40:29", "published_display": "29 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of MapLight Therapeutics, Inc. \u2013 NASDAQ:MPLT", "summary": "This article focuses on the \"Price to earnings forward\" metric for MapLight Therapeutics, Inc. (NASDAQ: MPLT). It is presented on a financial data platform page, likely from TradingView, indicating a focus on financial analysis for investors interested in the company's valuation.", "url": "https://www.tradingview.com/symbols/NASDAQ-MPLT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T21:10:59", "published_display": "28 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of MapLight Therapeutics, Inc. \u2013 NASDAQ:MPLT", "summary": "This article provides a brief mention of the \"Price to sales forward\" metric for MapLight Therapeutics, Inc. (NASDAQ: MPLT). It appears to be a financial data point available on TradingView, indicating a period value and changes in percentage.", "url": "https://www.tradingview.com/symbols/NASDAQ-MPLT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:10:05", "published_display": "28 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MPLT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of MapLight Therapeutics, Inc. (MPLT) stock, including its current price, analyst forecasts, historical performance, and financial data. It highlights that analysts predict a max estimate of $48.00 and a min estimate of $30.00 for MPLT's future p", "url": "https://www.tradingview.com/symbols/NASDAQ-MPLT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T09:09:47", "published_display": "26 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maplight Therapeutics (MPLT) Short Interest & Short Float | Updated Jun 2026", "summary": "Maplight Therapeutics (MPLT) reported a short interest of 1.90 million shares as of June 15, 2026, marking a 21.59% increase from the previous report and representing 4.63% of its public float. The short interest ratio (days to cover) stands at 6.5, indicating it would take this ", "url": "https://www.marketbeat.com/stocks/NASDAQ/MPLT/short-interest/", "source_name": "MarketBeat", "published_at": "2026-06-26T09:09:47", "published_display": "26 Jun 2026 09:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 MapLight Therapeutics Inc For: 25 June By Investing.com", "summary": "This article reports on the Form 4 filing for MapLight Therapeutics Inc. on June 25, indicating that the information is relevant for investors following insider transactions. It directly states the filing information and includes the company's stock performance details.", "url": "https://za.investing.com/news/stock-market-news/form-4-maplight-therapeutics-inc-for-25-june-93CH-4344959", "source_name": "Investing.com South Africa", "published_at": "2026-06-26T06:09:08", "published_display": "26 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics, Inc. Actuals & Estimates (NASDAQ:MPLT)", "summary": "This article provides key financial data and analyst estimates for MapLight Therapeutics, Inc. (NASDAQ: MPLT), including current stock price, market capitalization, historical performance, and future forecasts. It details the company's past earnings and revenue, upcoming earnings", "url": "https://www.tradingview.com/symbols/NASDAQ-MPLT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T03:09:47", "published_display": "26 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Raymond James Initiates Coverage on MapLight Therapeutics With Strong Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/raymond-james-initiates-coverage-maplight-113657992.html", "source_name": "MT Newswires", "published_at": "2026-06-25T11:36:57+00:00", "published_display": "25 Jun 2026 11:36", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix, MapLight are new Strong Buys at Raymond James on upcoming catalysts", "summary": "Raymond James has initiated coverage on Tonix Pharmaceuticals (TNXP) and MapLight Therapeutics (MPLT) with Strong Buy ratings, setting price targets of $26 and $46 per share, respectively. The analyst, Tiago Fauth, cited upcoming catalysts as the basis for these positive recommen", "url": "https://seekingalpha.com/news/4607308-tonix-maplight-new-strong-buys-raymond-james", "source_name": "Seeking Alpha", "published_at": "2026-06-25T10:54:00", "published_display": "25 Jun 2026 10:54", "sentiment": "positive", "sentiment_pct": 91, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics: The Cobenfy Challenger Does Not Look Like A Bargain (NASDAQ:MPLT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOaU1iZDV3b2gyZEx3TDhzODRPMXl4cHZVdjFrcjYtbWc1NXV3VDlpbDZRLXpiVVJjODU0SnpGTHhlRGswb2Vzc0JyNlphcHRkU3RWYUxQNmJKUHVCOHd6YmhsTHZmTk1mTkRwMmxRYWNyV2M4WHMyOGVoemYtME9xWnNIdHNOMC0yV2FVSjVfSEM4REN0MTFhaWkyanpRbWU4MVBlSzJvYkY0bGNsdkVjNWZrYw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics Appointed Martin Babler, Troy Cox to Bd >MPLT", "summary": "MapLight Therapeutics has announced the appointment of Martin Babler and Troy Cox to its Board of Directors. This move aims to strengthen the company's leadership as it continues to advance its therapeutic pipeline.", "url": "https://www.moomoo.com/news/post/71962788/maplight-therapeutics-appointed-martin-babler-troy-cox-to-bd-mplt", "source_name": "Moomoo", "published_at": "2026-06-24T13:10:30", "published_display": "24 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics appoints two directors to board", "summary": "MapLight Therapeutics (NASDAQ:MPLT) has appointed Martin Babler and Troy Cox to its Board of Directors following their election at the company\u2019s Annual Meeting of Stockholders on June 23, 2026. Babler joins the Audit Committee, while Cox will chair the Nominating and Corporate Go", "url": "https://www.investing.com/news/company-news/maplight-therapeutics-appoints-two-directors-to-board-93CH-4757848", "source_name": "Investing.com", "published_at": "2026-06-24T12:11:03", "published_display": "24 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics Announces Changes to Board of Directors", "summary": "MapLight Therapeutics has appointed Martin Babler and Troy Cox to its Board of Directors following their election at the Company\u2019s Annual Meeting of Stockholders on June 23, 2026. They succeed Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D. Mr. Babler will join the Audit Comm", "url": "https://www.manilatimes.net/2026/06/24/tmt-newswire/globenewswire/maplight-therapeutics-announces-changes-to-board-of-directors/2371800", "source_name": "The Manila Times", "published_at": "2026-06-24T11:11:03", "published_display": "24 Jun 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents", "summary": "MapLight Therapeutics Inc. (NASDAQ: MPLT) announced mixed results from its Phase 2 IRIS study of ML-004 for autism spectrum disorder, missing the primary endpoint for social communication but showing significant improvement in irritability for a subgroup of adolescents. The drug ", "url": "https://www.sahmcapital.com/news/content/maplight-therapeutics-autism-drug-shows-mixed-potential-in-adolescents-2026-06-22", "source_name": "Sahm", "published_at": "2026-06-23T14:10:06", "published_display": "23 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MPLT Maintained by Needham -- Price Target Raised to $42.00", "summary": "Needham analyst Ami Fadia has maintained a \"Buy\" rating for MapLight Therapeutics (MPLT) and raised the price target from $37.00 to $42.00, reflecting a positive outlook on the company's potential in treating central nervous system disorders. Despite this optimism, the company's ", "url": "https://www.gurufocus.com/news/8925574/mplt-maintained-by-needham-price-target-raised-to-4200", "source_name": "GuruFocus", "published_at": "2026-06-22T18:39:26", "published_display": "22 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight\u2019s autism drug trial misses primary endpoint", "summary": "MapLight Therapeutics Inc. (NASDAQ:MPLT) announced that its Phase 2 IRIS trial for ML-004 in autism spectrum disorder failed to achieve its primary endpoint, which was the improvement in social communication deficits. Despite this setback, the company's shares have shown resilien", "url": "https://www.investing.com/news/company-news/maplights-autism-drug-trial-misses-primary-endpoint-93CH-4752237", "source_name": "Investing.com", "published_at": "2026-06-22T13:09:08", "published_display": "22 Jun 2026 13:09", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics' Phase 2 Trial of ML-004 in Autism Spectrum Disorder Fails to Meet Primary Endpoint", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/maplight-therapeutics-apos-phase-2-115248933.html", "source_name": "MT Newswires", "published_at": "2026-06-22T11:52:48+00:00", "published_display": "22 Jun 2026 11:52", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/maplight-announces-topline-results-phase-110000597.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T11:00:00+00:00", "published_display": "22 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight reports Phase 2 autism trial results for ML-004", "summary": "MapLight announced that its Phase 2 trial of ML-004 for autism did not meet its primary endpoint, failing to improve caregiver-reported social communication scores in 161 patients. However, a prespecified subgroup analysis of 20 adolescent patients showed a statistically signific", "url": "https://grafa.com/en/news/united-states/maplight-therapeutics-ml004-autism-trial-results", "source_name": "grafa.com", "published_at": "2026-06-22T11:56:00", "published_display": "22 Jun 2026 11:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight\u2019s autism drug trial misses primary endpoint By Investing.com", "summary": "MapLight Therapeutics announced its Phase 2 IRIS trial for ML-004 in autism spectrum disorder failed to meet its primary endpoint, showing no significant improvement in social communication deficits. Despite the setback, the company's shares have risen significantly year-to-date,", "url": "https://ca.investing.com/news/stock-market-news/maplights-autism-drug-trial-misses-primary-endpoint-93CH-4700373", "source_name": "Investing.com Canada", "published_at": "2026-06-22T11:07:30", "published_display": "22 Jun 2026 11:07", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strong adolescent irritability signal in MapLight (MPLT) ML-004 Phase 2 IRIS trial", "summary": "MapLight Therapeutics announced mixed Phase 2 IRIS trial results for ML-004 in autism spectrum disorder. While the study did not meet its primary endpoint for social communication deficits, it showed a robust, clinically meaningful reduction in irritability among adolescents with", "url": "https://www.stocktitan.net/sec-filings/MPLT/8-k-map-light-therapeutics-inc-reports-material-event-7519c794e698.html", "source_name": "Stock Titan", "published_at": "2026-06-22T10:39:26", "published_display": "22 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is MapLight Therapeutics stock rallying today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNMUdIbURJQmZ0bjBJZ1QwdElocTdjUHJ1Unp6c0o2YVVvR3NVeDVDd25JSVpzSmw4bVkxNHUxQlhsOHM0bjJkODhxUEZQa3VkSVhEbEU3a3hKVmNoMlFNV3hvaV9rZlAxdFlMd3JyTklpRjB2TnBVVDI3TW4tWkh4cE0tcjhEcWp3S1FLTUFKMlMtOWYtakhMRlU0RGFFMFBPRUMyX3FVR2ZiRVRyNGoyag?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics, Inc.(NasdaqGS:MPLT) added to S&P Biotechnology Select Industry Index", "summary": "MapLight Therapeutics, Inc. (NasdaqGS: MPLT) has been added to the S&P Biotechnology Select Industry Index. This news follows several other recent announcements for the company, including executive appointments, analyst initiations with \"Buy\" ratings, and insider stock transactio", "url": "https://www.marketscreener.com/news/maplight-therapeutics-inc-nasdaqgs-mplt-added-to-s-p-biotechnology-select-industry-index-ce7f5cd3d88df32c", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T01:10:30", "published_display": "22 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maplight Therapeutics, Inc. Appoints Jonathan Gillis as Interim Principal Financial Officer, Effective June 18, 2026", "summary": "MapLight Therapeutics, Inc. has announced the appointment of Jonathan Gillis as its interim principal financial officer, effective June 18, 2026. Gillis, who currently serves as the company's Chief Administrative and Accounting Officer, will also maintain his role as principal ac", "url": "https://www.marketscreener.com/news/maplight-therapeutics-inc-appoints-jonathan-gillis-as-interim-principal-financial-officer-effecti-ce7f5cd2dd80fe2d", "source_name": "www.marketscreener.com", "published_at": "2026-06-19T10:39:14", "published_display": "19 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics Inc (MPLT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for MapLight Therapeutics Inc (MPLT), highlighting that 11 analysts currently rate the stock as a \"Buy\" with a target price indicating a 34.28% upside. The report includes key financial metrics like market cap, P/E TTM, and a comparison ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mplt/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T22:39:55", "published_display": "18 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing MapLight Therapeutics (MPLT) Valuation After Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNUm1DbXd0azh1NUUwZVJnWmtlLXU0djhXNWpHVkxzQ0VjYVY3NjZ5Nk5OZFpkd0F5SmtzS0NSdjFJaXdEbGlUOWU3YUIxb3VfT01nOWJqcUpuNVQyS3FfY3RfRzJ0Vm11SlB2YWZfdjBqOUpyMGVzUENoRENEaXo2d2dSR3NfMnNwXzFPeHZpX29Vd1AtbmN5Tk53YUVmdkNfU2dCRURsQ29rU1FlbUYzSzdJM3NNQWtaQ0swVzZ4NDBRalZxRDAySURRZjVWVGFkcm9fRU41VnU0YjEyV0t3YUx6WFdVVXEwVmfSAe8BQVVfeXFMUE9XTU5HTVNzYWVqWmRBZkVyU2lNcTBSaHhDTldUNVduWW5LeWFNbW5PdXRhRjUwMFplVGR2TGZOS3hhM0VLUEdTV1AwUkN6ZTdrRFVQRlhPVEFqUW1WUG00YTVqYW1zaFRnMHRTV1I2MTdGaUNnY0NaVFZGcUtjQmhDMWhVaVVyS0pUYjV4cFVyVVQ3eEYtOXNQODFJU1BpNWpGbWk2akRYenYycy1peEQ3QjdFY09sSktYS3JHTWV5SXIwQ2JHbGs4bHBMaHU4c19aMVRaM25oUWVwNFdNbWdsMVpBS1RweFVQV21DTFE?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean", "summary": "", "url": "https://finance.yahoo.com/m/3f58899c-8d3a-3ea4-b3bb-da879a909430/dyne-stock-is-up-56%25.-here%27s.html", "source_name": "Motley Fool", "published_at": "2026-05-30T16:48:24+00:00", "published_display": "30 May 2026 16:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MPLT - MapLight Therapeutics Inc Stock Price and Quote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiRkFVX3lxTE8xRFdoTTJtNm1oTkRDbXZvTll0SnB1ZWgyUHc0OENpUkk0UzJlNTBTYi1fT3BnQVJUTXdOcExhaXd4el9NUlE?oc=5", "source_name": "Finviz", "published_at": "2026-05-27T13:39:14+00:00", "published_display": "27 May 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UBS Initiates MapLight Therapeutics at Buy With $48 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ubs-initiates-maplight-therapeutics-buy-125313623.html", "source_name": "MT Newswires", "published_at": "2026-05-27T12:53:13+00:00", "published_display": "27 May 2026 12:53", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MPLT Stock Price and Chart \u2014 NASDAQ:MPLT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9CandWTWpmUGEtZWFQaXl4dVdRRmwwdk5FT0lrcmRjSHVBRG83N0hWUnFOYkZ4T283UHliQW9mY0pMR3UyRGxVem9wVDUxd2k4bXRGc3VHWllEa1ZR?oc=5", "source_name": "TradingView", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight lines up schizophrenia and autism trial results by mid-August", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQT2d5MVdfM1dGaWVFRWNOX0xqa3NvZ19vd01xbGhiOXFoRDdWN1Q1LUtLNmhjYUlLRDgtRTRmbm85MXhURHZzU2dpd2VyRWNsR3ktMktxdks3cVhQYVFRMWFPWFVLVnVSWHpuM0JTdjRTbkNWcnVOVHhrUVlWakYxaVBaeTNja28xOGgtOHgzRkxwekVJNFBkM0NObi00dkZJRjJ5bjhVMlFCSmFReGl6YTJfZlpqT04xM2ZIbWZpdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That MapLight Therapeutics (NASDAQ:MPLT) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZ241Q2J5bFNLQ25tTENtY05RSG9hcUlqREs1cHhzYkUtTVhkYlNEOUQwTWlIb2NES0F6d3VvTkNkLWFYdW5pZnBZcjF1ZkxhbXlLdERYOFRPZnhBN1hXZkEyS1VObDBQYW44YUU4U2Jzd3A2dWZ5MzRtdUNJODFCMG53TFJyT0RvckswVEpvemI2cFNZQ0ZaZnFPUko2ZE5YV0thY3ZrNFViQQ?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "$MPLT stock is up 11% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNQnlIT1FNemUweFBhaTR6ajF0cXpzTC1wMDVsaDkyZ1F3MUI1WHNDTFg4VWtlanY0TjNVMkNIbVVVYVB6WmRROEJMNk5sVm9kLUV4M2YzUmRnQm9MVjRCTVJZSFRSQTNYZVpwUlN3VDIyWnYxbThnOEZwVXNhUXZCeDIteHktX2NVeko3TEFfWmd0VjBFWXdUWFhyc0dDbUpm?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNN0FfUUxfRFJwd3JPUmVnTUtTU2c5cHVSLVJzcktpai1tMTRMcTlLWXE3bGk1X3MxaklsR3NJZld1NTA2QjlZQjlJVkRwcV9ULU9HbE5ucWtBblUwbk5nN3JJQUlLMjM1VWRyRUVNTllaZXBaczlEbDd3cGJTVlhPNEROSjhyX3BwWHpjcDJWYl9FT21XaS1PdnVCTEcwWXdnZ1NKcmF0X1JITGQxWnFhM3dhUlQzTk9nYWc?oc=5", "source_name": "The Motley Fool", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "TD Cowen Initiates on MapLight (MPLT); Says It\u2019s Undervalued on Schizophrenia Alone", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPNllUVEdoWU1TdmpIczV3YlVBSERaR0lUNnNtMEVRZGkxMTdMNlNuLUhZcEtjRGJEbVRieDdRa2hZQkE0aDZtTV9mRW50anBxcjBDOGgtdHptMFJROEYzdG5nNWFGZ0FvbUhrQXNlR09YWDc4Sy13eWZPY09ETEwxX2E1UW9STlkyZURtQ0IyVFpBQXVDTER0VTUtcGt4ZXVOa1lV?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics (MPLT): The Best Healthcare Stock Insiders Are Buying", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNNzVsdGFwX0k5djI3M1I2ZmF2OGVWdkU1MzNRNlM3LW9kUnh6Q004eDFONk1NQzFSVEgyM2kzYThqLWxxcDJSZ1JCcENuWlc0dk03WHFlbWR2V1AxZ1FPVnV5M3NBYU9GTDBPcVB2NzlHeW40UkxYUE5tUVMya3pMM1drZW4wRS1sSlZjNU9qY1VsaWR4MThRU002ZjV4X3djMG9wcnB1dUhFVk1BOWpWcw?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Form 144 MapLight Therapeutics For: 15 July By Investing.com", "summary": "This article reports on a Form 144 filing for MapLight Therapeutics on July 15. It is a very brief announcement, primarily consisting of the headline repeated in the body. The article originates from Investing.com and was published on July 15, 2026.", "url": "https://ng.investing.com/news/stock-market-news/form-144-maplight-therapeutics-for-15-july-93CH-2601605", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T21:14:00", "published_display": "15 Jul 2026 21:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maplight Therapeutics (NASDAQ:MPLT) Trading Down 5.4% - Here's What Happened", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPLTJOQjBVY1FhOFJHNFRmdUtXUU1TcnhmcVNLV1luVnUwQ210VnFxdTBTMjZXQ05SX05tZDdqc0JMX1NfU3NhazlTeVlWWXQ0ZjNBeTFvME5mbWp5anRibmxzcE9CRmZMRkRNZV9tUHJPU1p1bElnamtYNXBYWkllTW9fWkVaMzE3Mk96T0RKYmlOWHRkTW1tTW9tWlR4eER5dHA3NUhwN2c5N0dUX3prTm9fUVY0ekoxN2RrSXBLdw?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-15T16:26:57+00:00", "published_display": "15 Jul 2026 16:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Raises Target Price to $45", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNZEVNVkJ6T2k1Y21nR1J1Qlczakh1ZWxIVGJJRHQwbDE2NzZhOVVZNURrbEMxR2UzZ3AzbS1BUnJWcXh6enhtMGN2VnFLMmsxZVFmMjhSQ2V5TzZLejNBRGNIejk0dU1EV3VpX3hRMmgxNzhzZWRIcTZJaGpST19ua0VXNXZUb01Ga0k1RVlkZzRYaWxtTEVtQVVBR2lkSHJJc2Z2dWVWdnU5VzJORkRNdXdaUHJGSWJC?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-14T05:36:46+00:00", "published_display": "14 Jul 2026 05:36", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maplight Therapeutics (NASDAQ:MPLT) Sees Large Volume Increase on Analyst Upgrade", "summary": "Maplight Therapeutics (NASDAQ:MPLT) experienced a significant increase in trading volume after Needham & Company raised its price target and reaffirmed a buy rating. Despite positive analyst sentiment, with a consensus \"Buy\" rating and an average price target of $39.10, the compa", "url": "https://www.marketbeat.com/instant-alerts/maplight-therapeutics-nasdaqmplt-sees-large-volume-increase-on-analyst-upgrade-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T15:39:17", "published_display": "10 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham & Company LLC Raises Maplight Therapeutics (NASDAQ:MPLT) Price Target to $45.00", "summary": "Needham & Company LLC has increased its price target for Maplight Therapeutics (NASDAQ:MPLT) from $42.00 to $45.00, maintaining a \"buy\" rating and suggesting a 13.07% potential upside. This comes amidst a mixed analyst sentiment, with several firms reiterating \"buy\" ratings while", "url": "https://www.marketbeat.com/instant-alerts/needham-company-llc-raises-maplight-therapeutics-nasdaqmplt-price-target-to-4500-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T12:39:18", "published_display": "10 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham raises MapLight Therapeutics stock price target on trial data By Investing.com", "summary": "Needham has increased its price target for MapLight Therapeutics (NASDAQ:MPLT) to $45 from $42, maintaining a Buy rating. This adjustment comes as the firm raised the probability of success for MPLT's lead schizophrenia candidate, ML-007-MC, from 55% to 60%, with promising early ", "url": "https://ca.investing.com/news/stock-market-news/needham-raises-maplight-therapeutics-stock-price-target-on-trial-data-93CH-4729097", "source_name": "Investing.com Canada", "published_at": "2026-07-10T11:40:18", "published_display": "10 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MPLT - MapLight Therapeutics Inc Options", "summary": "This page provides a detailed financial overview of MapLight Therapeutics Inc (MPLT), including its last closing price, key financial metrics such as market cap, income, and sales, and various performance indicators. It also presents information on ownership, profitability, and s", "url": "https://finviz.com/stock?t=MPLT&ty=oc", "source_name": "Finviz", "published_at": "2026-07-05T05:41:23", "published_display": "05 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T15:08:06+00:00", "published_display": "04 Jul 2026 15:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of MapLight Therapeutics, Inc. \u2013 NASDAQ:MPLT", "summary": "This article focuses on the enterprise value to EBIT forward for MapLight Therapeutics, Inc. (NASDAQ: MPLT). It appears to be a financial data page from TradingView, providing financial oversight for the company. The content primarily lists navigation links and disclaimers rather", "url": "https://www.tradingview.com/symbols/NASDAQ-MPLT/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T08:11:24", "published_display": "01 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?", "summary": "MapLight Therapeutics, Inc. (MPLT) is considered a top biotech stock by analysts, with Raymond James initiating a \"Strong Buy\" rating and a $46 price target. The company has upcoming catalysts including the Phase 2 ZEPHYR trial readout for ML-007C-MA by mid-August and an Alzheime", "url": "https://uk.finance.yahoo.com/news/maplight-therapeutics-inc-mplt-stock-132231577.html", "source_name": "Market source", "published_at": "2026-06-30T15:38:59", "published_display": "30 Jun 2026 15:38", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of MapLight Therapeutics, Inc. \u2013 NASDAQ:MPLT", "summary": "This article provides details on how to find the number of shareholders for MapLight Therapeutics, Inc. (NASDAQ: MPLT) on TradingView. It directs users to the financial section of the company's profile where this information would typically be located, alongside other financial d", "url": "https://www.tradingview.com/symbols/NASDAQ-MPLT/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-30T04:09:31", "published_display": "30 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of MapLight Therapeutics, Inc. \u2013 NASDAQ:MPLT", "summary": "This article provides financial information for MapLight Therapeutics, Inc. (NASDAQ: MPLT), specifically focusing on its forward price-to-book ratio. The content states that the market for MPLT is currently closed with no trades. It appears to be a stub or data-oriented page from", "url": "https://www.tradingview.com/symbols/NASDAQ-MPLT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:40:29", "published_display": "29 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of MapLight Therapeutics, Inc. \u2013 NASDAQ:MPLT", "summary": "This article focuses on the \"Price to earnings forward\" metric for MapLight Therapeutics, Inc. (NASDAQ: MPLT). It is presented on a financial data platform page, likely from TradingView, indicating a focus on financial analysis for investors interested in the company's valuation.", "url": "https://www.tradingview.com/symbols/NASDAQ-MPLT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T21:10:59", "published_display": "28 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of MapLight Therapeutics, Inc. \u2013 NASDAQ:MPLT", "summary": "This article provides a brief mention of the \"Price to sales forward\" metric for MapLight Therapeutics, Inc. (NASDAQ: MPLT). It appears to be a financial data point available on TradingView, indicating a period value and changes in percentage.", "url": "https://www.tradingview.com/symbols/NASDAQ-MPLT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:10:05", "published_display": "28 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MPLT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of MapLight Therapeutics, Inc. (MPLT) stock, including its current price, analyst forecasts, historical performance, and financial data. It highlights that analysts predict a max estimate of $48.00 and a min estimate of $30.00 for MPLT's future p", "url": "https://www.tradingview.com/symbols/NASDAQ-MPLT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T09:09:47", "published_display": "26 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maplight Therapeutics (MPLT) Short Interest & Short Float | Updated Jun 2026", "summary": "Maplight Therapeutics (MPLT) reported a short interest of 1.90 million shares as of June 15, 2026, marking a 21.59% increase from the previous report and representing 4.63% of its public float. The short interest ratio (days to cover) stands at 6.5, indicating it would take this ", "url": "https://www.marketbeat.com/stocks/NASDAQ/MPLT/short-interest/", "source_name": "MarketBeat", "published_at": "2026-06-26T09:09:47", "published_display": "26 Jun 2026 09:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 MapLight Therapeutics Inc For: 25 June By Investing.com", "summary": "This article reports on the Form 4 filing for MapLight Therapeutics Inc. on June 25, indicating that the information is relevant for investors following insider transactions. It directly states the filing information and includes the company's stock performance details.", "url": "https://za.investing.com/news/stock-market-news/form-4-maplight-therapeutics-inc-for-25-june-93CH-4344959", "source_name": "Investing.com South Africa", "published_at": "2026-06-26T06:09:08", "published_display": "26 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics, Inc. Actuals & Estimates (NASDAQ:MPLT)", "summary": "This article provides key financial data and analyst estimates for MapLight Therapeutics, Inc. (NASDAQ: MPLT), including current stock price, market capitalization, historical performance, and future forecasts. It details the company's past earnings and revenue, upcoming earnings", "url": "https://www.tradingview.com/symbols/NASDAQ-MPLT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T03:09:47", "published_display": "26 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Raymond James Initiates Coverage on MapLight Therapeutics With Strong Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/raymond-james-initiates-coverage-maplight-113657992.html", "source_name": "MT Newswires", "published_at": "2026-06-25T11:36:57+00:00", "published_display": "25 Jun 2026 11:36", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tonix, MapLight are new Strong Buys at Raymond James on upcoming catalysts", "summary": "Raymond James has initiated coverage on Tonix Pharmaceuticals (TNXP) and MapLight Therapeutics (MPLT) with Strong Buy ratings, setting price targets of $26 and $46 per share, respectively. The analyst, Tiago Fauth, cited upcoming catalysts as the basis for these positive recommen", "url": "https://seekingalpha.com/news/4607308-tonix-maplight-new-strong-buys-raymond-james", "source_name": "Seeking Alpha", "published_at": "2026-06-25T10:54:00", "published_display": "25 Jun 2026 10:54", "sentiment": "positive", "sentiment_pct": 91, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics: The Cobenfy Challenger Does Not Look Like A Bargain (NASDAQ:MPLT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOaU1iZDV3b2gyZEx3TDhzODRPMXl4cHZVdjFrcjYtbWc1NXV3VDlpbDZRLXpiVVJjODU0SnpGTHhlRGswb2Vzc0JyNlphcHRkU3RWYUxQNmJKUHVCOHd6YmhsTHZmTk1mTkRwMmxRYWNyV2M4WHMyOGVoemYtME9xWnNIdHNOMC0yV2FVSjVfSEM4REN0MTFhaWkyanpRbWU4MVBlSzJvYkY0bGNsdkVjNWZrYw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics Appointed Martin Babler, Troy Cox to Bd >MPLT", "summary": "MapLight Therapeutics has announced the appointment of Martin Babler and Troy Cox to its Board of Directors. This move aims to strengthen the company's leadership as it continues to advance its therapeutic pipeline.", "url": "https://www.moomoo.com/news/post/71962788/maplight-therapeutics-appointed-martin-babler-troy-cox-to-bd-mplt", "source_name": "Moomoo", "published_at": "2026-06-24T13:10:30", "published_display": "24 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics appoints two directors to board", "summary": "MapLight Therapeutics (NASDAQ:MPLT) has appointed Martin Babler and Troy Cox to its Board of Directors following their election at the company\u2019s Annual Meeting of Stockholders on June 23, 2026. Babler joins the Audit Committee, while Cox will chair the Nominating and Corporate Go", "url": "https://www.investing.com/news/company-news/maplight-therapeutics-appoints-two-directors-to-board-93CH-4757848", "source_name": "Investing.com", "published_at": "2026-06-24T12:11:03", "published_display": "24 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics Announces Changes to Board of Directors", "summary": "MapLight Therapeutics has appointed Martin Babler and Troy Cox to its Board of Directors following their election at the Company\u2019s Annual Meeting of Stockholders on June 23, 2026. They succeed Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D. Mr. Babler will join the Audit Comm", "url": "https://www.manilatimes.net/2026/06/24/tmt-newswire/globenewswire/maplight-therapeutics-announces-changes-to-board-of-directors/2371800", "source_name": "The Manila Times", "published_at": "2026-06-24T11:11:03", "published_display": "24 Jun 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents", "summary": "MapLight Therapeutics Inc. (NASDAQ: MPLT) announced mixed results from its Phase 2 IRIS study of ML-004 for autism spectrum disorder, missing the primary endpoint for social communication but showing significant improvement in irritability for a subgroup of adolescents. The drug ", "url": "https://www.sahmcapital.com/news/content/maplight-therapeutics-autism-drug-shows-mixed-potential-in-adolescents-2026-06-22", "source_name": "Sahm", "published_at": "2026-06-23T14:10:06", "published_display": "23 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MPLT Maintained by Needham -- Price Target Raised to $42.00", "summary": "Needham analyst Ami Fadia has maintained a \"Buy\" rating for MapLight Therapeutics (MPLT) and raised the price target from $37.00 to $42.00, reflecting a positive outlook on the company's potential in treating central nervous system disorders. Despite this optimism, the company's ", "url": "https://www.gurufocus.com/news/8925574/mplt-maintained-by-needham-price-target-raised-to-4200", "source_name": "GuruFocus", "published_at": "2026-06-22T18:39:26", "published_display": "22 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight\u2019s autism drug trial misses primary endpoint", "summary": "MapLight Therapeutics Inc. (NASDAQ:MPLT) announced that its Phase 2 IRIS trial for ML-004 in autism spectrum disorder failed to achieve its primary endpoint, which was the improvement in social communication deficits. Despite this setback, the company's shares have shown resilien", "url": "https://www.investing.com/news/company-news/maplights-autism-drug-trial-misses-primary-endpoint-93CH-4752237", "source_name": "Investing.com", "published_at": "2026-06-22T13:09:08", "published_display": "22 Jun 2026 13:09", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics' Phase 2 Trial of ML-004 in Autism Spectrum Disorder Fails to Meet Primary Endpoint", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/maplight-therapeutics-apos-phase-2-115248933.html", "source_name": "MT Newswires", "published_at": "2026-06-22T11:52:48+00:00", "published_display": "22 Jun 2026 11:52", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/maplight-announces-topline-results-phase-110000597.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T11:00:00+00:00", "published_display": "22 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight reports Phase 2 autism trial results for ML-004", "summary": "MapLight announced that its Phase 2 trial of ML-004 for autism did not meet its primary endpoint, failing to improve caregiver-reported social communication scores in 161 patients. However, a prespecified subgroup analysis of 20 adolescent patients showed a statistically signific", "url": "https://grafa.com/en/news/united-states/maplight-therapeutics-ml004-autism-trial-results", "source_name": "grafa.com", "published_at": "2026-06-22T11:56:00", "published_display": "22 Jun 2026 11:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight\u2019s autism drug trial misses primary endpoint By Investing.com", "summary": "MapLight Therapeutics announced its Phase 2 IRIS trial for ML-004 in autism spectrum disorder failed to meet its primary endpoint, showing no significant improvement in social communication deficits. Despite the setback, the company's shares have risen significantly year-to-date,", "url": "https://ca.investing.com/news/stock-market-news/maplights-autism-drug-trial-misses-primary-endpoint-93CH-4700373", "source_name": "Investing.com Canada", "published_at": "2026-06-22T11:07:30", "published_display": "22 Jun 2026 11:07", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strong adolescent irritability signal in MapLight (MPLT) ML-004 Phase 2 IRIS trial", "summary": "MapLight Therapeutics announced mixed Phase 2 IRIS trial results for ML-004 in autism spectrum disorder. While the study did not meet its primary endpoint for social communication deficits, it showed a robust, clinically meaningful reduction in irritability among adolescents with", "url": "https://www.stocktitan.net/sec-filings/MPLT/8-k-map-light-therapeutics-inc-reports-material-event-7519c794e698.html", "source_name": "Stock Titan", "published_at": "2026-06-22T10:39:26", "published_display": "22 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is MapLight Therapeutics stock rallying today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNMUdIbURJQmZ0bjBJZ1QwdElocTdjUHJ1Unp6c0o2YVVvR3NVeDVDd25JSVpzSmw4bVkxNHUxQlhsOHM0bjJkODhxUEZQa3VkSVhEbEU3a3hKVmNoMlFNV3hvaV9rZlAxdFlMd3JyTklpRjB2TnBVVDI3TW4tWkh4cE0tcjhEcWp3S1FLTUFKMlMtOWYtakhMRlU0RGFFMFBPRUMyX3FVR2ZiRVRyNGoyag?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics, Inc.(NasdaqGS:MPLT) added to S&P Biotechnology Select Industry Index", "summary": "MapLight Therapeutics, Inc. (NasdaqGS: MPLT) has been added to the S&P Biotechnology Select Industry Index. This news follows several other recent announcements for the company, including executive appointments, analyst initiations with \"Buy\" ratings, and insider stock transactio", "url": "https://www.marketscreener.com/news/maplight-therapeutics-inc-nasdaqgs-mplt-added-to-s-p-biotechnology-select-industry-index-ce7f5cd3d88df32c", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T01:10:30", "published_display": "22 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maplight Therapeutics, Inc. Appoints Jonathan Gillis as Interim Principal Financial Officer, Effective June 18, 2026", "summary": "MapLight Therapeutics, Inc. has announced the appointment of Jonathan Gillis as its interim principal financial officer, effective June 18, 2026. Gillis, who currently serves as the company's Chief Administrative and Accounting Officer, will also maintain his role as principal ac", "url": "https://www.marketscreener.com/news/maplight-therapeutics-inc-appoints-jonathan-gillis-as-interim-principal-financial-officer-effecti-ce7f5cd2dd80fe2d", "source_name": "www.marketscreener.com", "published_at": "2026-06-19T10:39:14", "published_display": "19 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics Inc (MPLT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for MapLight Therapeutics Inc (MPLT), highlighting that 11 analysts currently rate the stock as a \"Buy\" with a target price indicating a 34.28% upside. The report includes key financial metrics like market cap, P/E TTM, and a comparison ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mplt/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T22:39:55", "published_display": "18 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing MapLight Therapeutics (MPLT) Valuation After Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean", "summary": "", "url": "https://finance.yahoo.com/m/3f58899c-8d3a-3ea4-b3bb-da879a909430/dyne-stock-is-up-56%25.-here%27s.html", "source_name": "Motley Fool", "published_at": "2026-05-30T16:48:24+00:00", "published_display": "30 May 2026 16:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MPLT - MapLight Therapeutics Inc Stock Price and Quote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiRkFVX3lxTE8xRFdoTTJtNm1oTkRDbXZvTll0SnB1ZWgyUHc0OENpUkk0UzJlNTBTYi1fT3BnQVJUTXdOcExhaXd4el9NUlE?oc=5", "source_name": "Finviz", "published_at": "2026-05-27T13:39:14+00:00", "published_display": "27 May 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UBS Initiates MapLight Therapeutics at Buy With $48 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ubs-initiates-maplight-therapeutics-buy-125313623.html", "source_name": "MT Newswires", "published_at": "2026-05-27T12:53:13+00:00", "published_display": "27 May 2026 12:53", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MPLT Stock Price and Chart \u2014 NASDAQ:MPLT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9CandWTWpmUGEtZWFQaXl4dVdRRmwwdk5FT0lrcmRjSHVBRG83N0hWUnFOYkZ4T283UHliQW9mY0pMR3UyRGxVem9wVDUxd2k4bXRGc3VHWllEa1ZR?oc=5", "source_name": "TradingView", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight lines up schizophrenia and autism trial results by mid-August", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQT2d5MVdfM1dGaWVFRWNOX0xqa3NvZ19vd01xbGhiOXFoRDdWN1Q1LUtLNmhjYUlLRDgtRTRmbm85MXhURHZzU2dpd2VyRWNsR3ktMktxdks3cVhQYVFRMWFPWFVLVnVSWHpuM0JTdjRTbkNWcnVOVHhrUVlWakYxaVBaeTNja28xOGgtOHgzRkxwekVJNFBkM0NObi00dkZJRjJ5bjhVMlFCSmFReGl6YTJfZlpqT04xM2ZIbWZpdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That MapLight Therapeutics (NASDAQ:MPLT) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZ241Q2J5bFNLQ25tTENtY05RSG9hcUlqREs1cHhzYkUtTVhkYlNEOUQwTWlIb2NES0F6d3VvTkNkLWFYdW5pZnBZcjF1ZkxhbXlLdERYOFRPZnhBN1hXZkEyS1VObDBQYW44YUU4U2Jzd3A2dWZ5MzRtdUNJODFCMG53TFJyT0RvckswVEpvemI2cFNZQ0ZaZnFPUko2ZE5YV0thY3ZrNFViQQ?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$MPLT stock is up 11% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNQnlIT1FNemUweFBhaTR6ajF0cXpzTC1wMDVsaDkyZ1F3MUI1WHNDTFg4VWtlanY0TjNVMkNIbVVVYVB6WmRROEJMNk5sVm9kLUV4M2YzUmRnQm9MVjRCTVJZSFRSQTNYZVpwUlN3VDIyWnYxbThnOEZwVXNhUXZCeDIteHktX2NVeko3TEFfWmd0VjBFWXdUWFhyc0dDbUpm?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNN0FfUUxfRFJwd3JPUmVnTUtTU2c5cHVSLVJzcktpai1tMTRMcTlLWXE3bGk1X3MxaklsR3NJZld1NTA2QjlZQjlJVkRwcV9ULU9HbE5ucWtBblUwbk5nN3JJQUlLMjM1VWRyRUVNTllaZXBaczlEbDd3cGJTVlhPNEROSjhyX3BwWHpjcDJWYl9FT21XaS1PdnVCTEcwWXdnZ1NKcmF0X1JITGQxWnFhM3dhUlQzTk9nYWc?oc=5", "source_name": "The Motley Fool", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen Initiates on MapLight (MPLT); Says It\u2019s Undervalued on Schizophrenia Alone", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPNllUVEdoWU1TdmpIczV3YlVBSERaR0lUNnNtMEVRZGkxMTdMNlNuLUhZcEtjRGJEbVRieDdRa2hZQkE0aDZtTV9mRW50anBxcjBDOGgtdHptMFJROEYzdG5nNWFGZ0FvbUhrQXNlR09YWDc4Sy13eWZPY09ETEwxX2E1UW9STlkyZURtQ0IyVFpBQXVDTER0VTUtcGt4ZXVOa1lV?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MapLight Therapeutics (MPLT): The Best Healthcare Stock Insiders Are Buying", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNNzVsdGFwX0k5djI3M1I2ZmF2OGVWdkU1MzNRNlM3LW9kUnh6Q004eDFONk1NQzFSVEgyM2kzYThqLWxxcDJSZ1JCcENuWlc0dk03WHFlbWR2V1AxZ1FPVnV5M3NBYU9GTDBPcVB2NzlHeW40UkxYUE5tUVMya3pMM1drZW4wRS1sSlZjNU9qY1VsaWR4MThRU002ZjV4X3djMG9wcnB1dUhFVk1BOWpWcw?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 74, "sentiment_summary": {"positive": 21, "negative": 6, "neutral": 47, "score": 55, "total": 74, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 21.4, "count": 37}, {"event": "earnings", "label": "Earnings", "weight": 11.9, "count": 23}, {"event": "analyst", "label": "Analyst action", "weight": 6.4, "count": 11}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 39.32, "latest_week": "2026-07-10", "one_week_move": 6.0, "four_week_move": 41.7, "twelve_week_move": 30.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.004943, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": 75.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 58.8859, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.0% over one week, +41.7% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "TradingView", "count": 9}, {"label": "MarketBeat", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Investing.com Canada", "count": 2}, {"label": "Finviz", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 66}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 37}, {"label": "Earnings", "count": 23}, {"label": "Analyst action", "count": 11}, {"label": "Deals and strategy", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "66", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+6.0% over one week, +41.7% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Form 144 MapLight Therapeutics For: 15 July By Investing.com"}], "updated_at": "2026-07-18T00:59:04.894723+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}